Brief: Nymox Pharmaceutical says European member states accepted MAA for fexapotide triflutate
14/09/2017 17:40
Sept 14 (Reuters) - Nymox Pharmaceutical Corp NYMX.O
* Says European member states for Nymox's MAA for
fexapotide triflutate for treatment of benign prostatic
hyperplasia accepted co's MAA
Source text for Eikon: ID:nGNXOEGKQa
Further company coverage: NYMX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba